Open AccessTicagrelor Monotherapy After 3-Month Dual Antiplatelet Therapy in Acute Coronary Syndrome by High Bleeding Risk: The Subanalysis From the TICO Trial
Author(s) -
Yong-Joon Lee,
Yongsung Suh,
Jung Sun Kim,
Yun-Hyeong Cho,
Kyeong Ho Yun,
Yong Hoon Kim,
Jae Young Cho,
Ae Young Her,
Sungsoo Cho,
Dong Woon Jeon,
Sang-Yong Yoo,
Deok-Kyu Cho,
Bum–Kee Hong,
Hyuck Moon Kwon,
Sung Jin Hong,
ChulMin Ahn,
Dong Ho Shin,
Chung Mo Nam,
ByeongKeuk Kim,
Young Guk Ko,
Donghoon Choi,
Myeong Ki Hong,
Yangsoo Jang,
AUTHOR_ID
Publication year - 2022
Publication title -
korean circulation journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.809
H-Index - 29
eISSN - 1738-5555
pISSN - 1738-5520
DOI - 10.4070/kcj.2021.0321
Subject(s) - medicine , ticagrelor , hazard ratio , acute coronary syndrome , adverse effect , cardiology , confidence interval , myocardial infarction
Identifying patients with high bleeding risk (HBR) is important when making decisions for antiplatelet therapy strategy. This study evaluated the impact of ticagrelor monotherapy after 3-month dual antiplatelet therapy (DAPT) according to HBR in acute coronary syndrome (ACS) patients treated with drug eluting stents (DESs).